Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 251-258

  Day, Joanna M ^a   Tutill, Helena J ^a   Foster, Paul A ^a   Bailey, Helen V ^b   Heaton, Wesley B ^b   Sharland, Christopher M ^b   Vicker, Nigel ^b   Potter, Barry V L ^b   Purohit, Atul ^a   Reed, Michael J ^a  

^a Sterix Ltd   (United Kingdom)

^b University of Bath   (United Kingdom)

Author keywords

17 Hydroxysteroid dehydrogenase (17 HSD); Androgen; Enzyme inhibition; Prostate cancer; Testosterone

Indexed keywords

5 ALPHA DIHYDROTESTOSTERONE; ANDROGEN RECEPTOR; ENZYME INHIBITOR; STX 2171; STX 2622; STX 2624; TESTOSTERONE 17BETA DEHYDROGENASE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIOMETRY; XENOGRAFT;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HORMONES; HUMANS; MALE; MICE; PROSTATIC NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60249088055     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.014     Document Type: Article

References (48)

1. Akaza H. Adjuvant goserelin improves clinical disease-free survival and reduces disease-related mortality in patients with locally advanced or localized prostate cancer. Brit. J. Urol. Int. 93 (2004) 42-46
2. Andersson S., and Moghrabi N. Physiology and molecular genetics of 17β-hydroxysteroid dehydrogenases. Steroids 62 (1997) 143-147
3. Bérubé M., and Poirier D. Chemical synthesis and in vitro biological evaluation of a phosphorylated bisubstrate inhibitor of type 3 17β-hydroxysteroid dehydrogenase. J. Enzyme Inhib. Med. Chem. 22 (2007) 201-211
4. Biancolella M., Valentini A., Minella D., Vecchione L., D'Amico F., Chillemi G., Gravina P., Bueno S., Prosperini G., Desideri A., Federici G., Bernardini S., and Novelli G. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines. Invest. New Drugs 25 (2007) 491-497
5. Day J.M., Tutill H.J., Newman S.P., Purohit A., Lawrence H.R., Vicker N., Potter B.V.L., and Reed M.J. 17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines. Mol. Cell. Endocrinol. 248 (2006) 246-249
6. Day J.M., Foster P.A., Chander S.K., Tutill H.J., Parsons M.F.C., Allan G.M., Lawrence H.R., Vicker N., Potter B.V.L., Reed M.J., and Purohit A. Inhibition of estrone-dependent tumor growth in vivo by the 17β-HSD1 inhibitor, 2-ethyl-16β-m-pyridylmethylamidomethyl-estrone (2-EtE1-F). Breast Cancer Res. Treat. 100 (2006) S197
7. Day J.M., Tutill H.J., Purohit A., and Reed M.J. Design and validation of specific inhibitors of 17β-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr. Relat. Cancer 15 (2008) 665-692
8. Day J.M., Foster P.A., Tutill H.J., Parsons M.F.C., Newman S.P., Chander S.K., Allan G.M., Lawrence H.R., Vicker N., Potter B.V.L., Reed M.J., and Purohit A. 17β-Hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int. J. Cancer 122 (2008) 1931-1940
9. Duax W.L., Thomas J., Pletnev V., Addlagatta A., Huether R., Habegger L., and Weeks C.M. Determining structure and function of steroid dehydrogenase enzymes by sequence analysis, homology modeling, and rational mutational analysis. Ann. NY Acad. Sci. 1061 (2005) 135-148
10. Fink B.E., Gavai A.V., Tokarski J.S., Goyal B., Misra R., Xiao H.Y., Kimball S.D., Han W.C., Norris D., Spires T.E., You D., Gottardis M.M., Lorenzi M.V., and Vite G.D. Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17β-hydroxysteroid dehydrogenase type 3. Bioorg. Med. Chem. Lett. 16 (2006) 1532-1536
11. Fradet Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Expert Rev. Anticancer Ther. 4 (2004) 37-48
12. Geissler W.M., Davis D.L., Wu L., Bradshaw K.D., Patel S., Mendonca B.B., Elliston K.O., Wilson J.D., Russell D.W., and Andersson S. Male pseudohermaphroditism caused by mutations of testicular 17β-hydroxysteroid dehydrogenase 3. Nat. Genet. 7 (1994) 34-39
13. Gnatenko D.V., Cupit L.D., Huang E.C., Dhundale A., Perrotta P.L., and Bahou W.F. Platelets express steroidogenic 17β-hydroxysteroid dehydrogenases: distinct profiles predict the essential thrombocythemic phenotype. Thromb. Haemost. 94 (2005) 412-421
14. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., and Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 43 (1983) 1809-1818
15. Husen B., Huhtinen K., Poutanen M., Kangas L., Messinger J., and Thole H. Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol. Cell. Endocrinol. 248 (2006) 109-113
16. Jansson A.K., Gunnarsson C., Cohen M., Sivik T., and Stål O. 17β-Hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res. 66 (2006) 11471-11477
17. Khan N., Sharma K.K., Andersson S., and Auchus R.J. Human 17β-hydroxysteroid dehydrogenases types 1,2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells. Arch. Biochem. Biophys. 429 (2004) 50-59
18. Koh E., Noda T., Kanaya J., and Namiki M. Differential expression of 17β-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 (2002) 154-159
19. Komoto J., Yamada T., Watanabe K., and Takusagawa F. Crystal structure of human prostaglandin F synthase (AKR1C3). Biochemistry 43 (2004) 2188-2198
20. Laplante Y., and Poirier D. Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line. Steroids 73 (2008) 266-271
21. Le Lain R., Barrell K.J., Saeed G.S., Nicholls P.J., Simons C., Kirby A., and Smith H.J. Some coumarins and triphenylethene derivatives as inhibitors of human testes microsomal 17β-hydroxysteroid dehydrogenase (17β-HSD type 3): further studies with tamoxifen on the rat testes microsomal enzyme. J. Enzyme Inhib. Med. Chem. 17 (2002) 93-100
22. Lota R.K., Dhanani S., Owen C.P., and Ahmed S. Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a series of 4-hydroxyphenyl ketones as potential inhibitors of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3). Bioorg. Med. Chem. Lett. 16 (2006) 4519-4522
23. Lukacik P., Kavanagh K.L., and Oppermann U. Structure and function of human 17β-hydroxysteroid dehydrogenases. Mol. Cell. Endocrinol. 248 (2006) 61-71
24. Luu-The V., Zhang Y., Poirier D., and Labrie F. Characteristics of human types 1,2 and 3 17β-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition. J. Steroid Biochem. Mol. Biol. 55 (1995) 581-587
25. Luu-The V., Tremblay P., and Labrie F. Characterization of type 12 17β-hydroxysteroid dehydrogenase, an isoform of type 3 17β-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol. Endocrinol. 20 (2006) 437-443
26. Luu-The V., Belanger A., and Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract. Res. Clin. Endocrinol. Metab. 22 (2008) 207-221
27. Macdiarmid F., Wang D., Duncan L.J., Purohit A., Ghilchick M.W., and Reed M.J. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor alpha. Mol. Cell. Endocrinol. 106 (1994) 17-21
28. Maltais R., Luu-The V., and Poirier D. Synthesis and optimization of a new family of type 3 17β-hydroxysteroid dehydrogenase inhibitors by parallel liquid-phase chemistry. J. Med. Chem. 45 (2002) 640-653
29. Margiotti K., Kim E., Pearce C.L., Spera E., Novelli G., and Reichardt J.K. Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. Prostate 53 (2002) 65-68
30. Mizokami A., Koh E., Fujita H., Maeda Y., Egawa M., Koshida K., Honma S., Keller E.T., and Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 64 (2004) 765-771
31. Moon Y.-A., and Horton J.D. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J. Biol. Chem. 278 (2003) 7335-7343
32. Pelletier G., Luu-The V., Têtu B., and Labrie F. Immunocytochemical localization of type 5 17β-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem. Cytochem. 47 (1999) 731-737
33. Peltoketo H., Luu-The V., Simard J., and Adamski J. 17β-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol. 23 (1999) 1-11
34. Penning T.M. 17β-Hydroxysteroid dehydrogenase inhibitors and inhibitor design. Endocr. Rel. Cancer 3 (1996) 41-56
35. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., Moore M., Palackal N., and Ratnam K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem. J. 351 (2000) 67-77
36. Pienta K.J., and Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12 (2006) 1665-1671
37. Poirier D. Inhibitors of 17β-hydroxysteroid dehydrogenases. Curr. Med. Chem. 10 (2003) 453-477
38. Rau K.M., Kang H.Y., Cha T.L., Miller S.A., and Hung M.C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr. Relat. Cancer 12 (2005) 511-532
39. Shi R., and Lin S.X. Cofactor hydrogen bonding onto the protein main chain is conserved in the short chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J. Biol. Chem. 279 (2004) 16778-16785
40. Stanway S.J., Purohit A., Woo L.W., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V.L., Reed M.J., and Coombes R.C. Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12 (2006) 1585-1592
41. Tchédam Ngatcha B., Luu-The V., Labrie F., and Poirier D. Androsterone 3α-ether-3β-substituted and androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem. 48 (2005) 5257-5268
42. Tindall D.J., and Rittmaster R.S. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J. Urol. 179 (2008) 1235-1242
43. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestesterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11 (2005) 4653-4657
44. Veldscholte J., Berrevoets C.A., Brinkmann A.O., Grootegoed J.A., and Mulder E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 31 (1992) 2393-2399
45. Vicker, N., Day, J.M., Bailey, H.V., Heaton, W., Gonzalez, A.M.R., Sharland, C.M., Reed, M.J., Purohit, A., Potter, B.V.L., 2007. Preparation of substituted aliphatic amines for use as anticancer or therapeutic agents inhibiting 17β-hydroxysteroid dehydrogenase. WO 2007003934 A2.
46. Vicker N., Sharland C.M., Heaton W.B., Ramos A.M., Bailey H.V., Smith A., Springall J.S., Day J.M., Tutill H.J., Reed M.J., Purohit A., and Potter B.V.L. The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors. Mol. Cell. Endocrinol. 301 (2009) 259-265
47. Vihko P., Herrala A., Härkönen P., Isomaa V., Kaija H., Kurkela R., and Pulkka A. Control of cell proliferation by steroids: the role of 17HSDs. Mol. Cell. Endocrinol. 248 (2006) 141-148
48. Yale H.L., Sowinski F., and Spitzmiller E.R. Novel polycyclic heterocycles. VIII. 6,11-Dihydro-12H-dibenzo[b,f][1,4]thazocines and their derivatives. J. Heterocycl. Chem. 9 (1972) 899